Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock Has Consensus Price Target of $7.50 According to Analysts

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have been given an average recommendation of “Hold” by the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $7.50.

CRDF has been the subject of several research reports. Weiss Ratings downgraded shares of Cardiff Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 23rd. William Blair downgraded shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a report on Tuesday, August 11th. HC Wainwright raised shares of Cardiff Oncology from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 15th. Finally, Wall Street Zen raised shares of Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th.

Cardiff Oncology Stock Up 5.3%

NASDAQ:CRDF traded up $0.04 on Friday, hitting $0.80. The stock had a trading volume of 345,291 shares, compared to its average volume of 416,305. Cardiff Oncology has a 52 week low of $0.75 and a 52 week high of $3.31. The business’s fifty day moving average is $1.07 and its 200 day moving average is $1.40. The company has a market cap of $61.87 million, a PE ratio of -1.33 and a beta of 1.57.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Cardiff Oncology had a negative net margin of 7,885.43% and a negative return on equity of 103.10%. The firm had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.06 million. Equities analysts predict that Cardiff Oncology will post -0.60 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cardiff Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Cardiff Oncology in the 2nd quarter valued at about $1,265,000. GoalVest Advisory LLC acquired a new position in Cardiff Oncology during the 3rd quarter valued at about $832,000. Flputnam Investment Management Co. acquired a new position in Cardiff Oncology during the 2nd quarter valued at about $322,000. X Square Capital LLC bought a new stake in Cardiff Oncology during the 2nd quarter worth approximately $267,000. Finally, GSA Capital Partners LLP bought a new stake in Cardiff Oncology during the 2nd quarter worth approximately $225,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead product candidate is onvansertib, an oral, selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cancer-cell division.

Cardiff Oncology has primarily evaluated onvansertib in combination with standard treatments for patients with RAS-mutated metastatic colorectal cancer, including investigations involving KRAS-mutated disease. The company has also explored the candidate in other solid tumors, including metastatic castration-resistant prostate cancer.